Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum

Table 2

Patient demographics and effusion mesothelin and MPF concentrations in MM patients and controls.

Group	Number of cases (number of females)	Mean age, years (range)	Effusion mesothelin (nM)^a,c	Effusion MPF (ng/mL)^a,b,c
MM	43 (6)	71 (42–88)	𝟑𝟓.𝟏±𝟕.𝟐	𝟏𝟒𝟔𝟒±𝟐𝟏𝟗
Non-MM malignant effusions	79 (47)	70 (37–96)	𝟕.𝟏±𝟎.𝟕^∗∗∗	𝟐𝟏𝟎±𝟐𝟑^∗∗∗
Lung cancer	42 (17)	72 (48–92)	6.4±0.9^∗∗∗	198±25^∗∗∗
Breast cancer	19 (19)	65 (37–96)	5.8±0.8^∗∗∗	201±32^∗∗∗
Ovarian cancer	11 (11)	66 (42–86)	12.2±4.1^ns	188±93^∗∗∗
Pancreatic cancer	7 (0)	64 (56–75)	9.9±2.6^ns	420±147^∗∗
Benign effusions	143 (39)	66 (19–96)	𝟐.𝟕±𝟎.𝟖^∗∗∗	𝟗𝟔±𝟏𝟎^∗∗∗
ARD	16 (1)	74 (50–91)	5.5±0.8^∗∗∗	170±20^∗∗∗
Exudate	51 (12)	65 (19–94)	2.9±0.4^∗∗∗	107±14^∗∗∗
Infection	42 (10)	64 (30–96)	2.0±0.3^∗∗∗	48±13^∗∗∗
Transudate	34 (16)	71 (12–93)	4.0±0.6^∗∗∗	148±14^∗∗∗

aexponentiated mean of log transformed data plus/minus standard error of log transformed data *100.
^bMPF concentrations determined from Human MPF Assay (MBL).
^csignificant difference between indicated cohorts and mesothelioma group as a whole (𝑛=43) as determined by Student’s 𝑡-test (ns is not significant; ** is 𝑃<0.001; and *** is 𝑃<0.0001).